Skip to content
Cart

Your Cart

×

You have 0 items in your cart.

Register Sign in Wishlist

Essential CNS Drug Development

£93.00

Sheldon H. Preskorn, Gwen L. Zornberg, Alan J. Cross, Frank D. Yocca, Matthew Macaluso, Michael Krams, Douglas E. Feltner, Kenneth R. Evans, Judith Dunn, Penny Randall, Amir Kalali, Craig H. Mallinckrodt, William R. Prucka, Geert Molenberghs, Nuala Murphy, Joseph Kwentus, Ginette Nachman, Leslie Citrome, Philip D. Harvey, Richard S. E. Keefe
View all contributors
  • Date Published: June 2012
  • availability: Available
  • format: Hardback
  • isbn: 9780521766067

£ 93.00
Hardback

Add to cart Add to wishlist

Other available formats:
eBook


Looking for an inspection copy?

This title is not currently available on inspection

Description
Product filter button
Description
Contents
Resources
Courses
About the Authors
  • Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way that is engaging for any interested professional or student. Chapters cover each stage of drug development, from pre-clinical research through all phases of clinical trials, to reporting to the regulatory authorities. Other key issues covered include strategic considerations, regulatory constraints, dissemination of results and ethical considerations. The user-friendly format and style enable readers to find important information quickly and easily. Written and edited by experts from different sectors actively engaged in CNS drug development, this is a unique resource for drug developers, investigators, academics and clinicians.

    • Describes the entire process of drug development, including detailed coverage of each phase of the pre-clinical research and clinical trials
    • Provides both detailed content for experienced drug developers and an accessible overview of use to newcomers to the field
    • Previews future trends in CNS drug development, from expert authors and editors who work at the cutting edge of their disciplines
    Read more

    Reviews & endorsements

    'The experienced authors admirably describe the art and skills of managing the constraints of recruitment criteria, prioritising participant welfare, and balancing budgetary concerns … The volume can be recommended for the libraries of senior investigators who are training the next generation as a stimulus in the supervisory process. The text also offers a springboard for discussions among policy makers themselves, hopefully promoting an insight that they are overdue in their effort to overhaul a system nearly imploding under ponderous, regulatory, protectionistic, and, unfortunately, often minimally scientific burdens of multiple financial and other interests. The brief format is highly readable, more concise than comprehensive in scope, providing more of an overview of the issues than would be expected from a formal reference text … Overall, the editors offer a timely discussion of many strengths and weaknesses of a highly regulated and cumbersome process.' Ronald M. Salomon, Journal of Clinical Psychiatry

    Customer reviews

    Not yet reviewed

    Be the first to review

    Review was not posted due to profanity

    ×

    , create a review

    (If you're not , sign out)

    Please enter the right captcha value
    Please enter a star rating.
    Your review must be a minimum of 12 words.

    How do you rate this item?

    ×

    Product details

    • Date Published: June 2012
    • format: Hardback
    • isbn: 9780521766067
    • length: 215 pages
    • dimensions: 240 x 161 x 15 mm
    • weight: 0.52kg
    • contains: 27 b/w illus. 5 colour illus. 23 tables
    • availability: Available
  • Table of Contents

    Preface
    1. History of CNS drug development Sheldon H. Preskorn
    2. Regulatory issues Gwen L. Zornberg
    3. Pre-clinical development Alan J. Cross and Frank D. Yocca
    4. Phase I trials: from traditional to newer approaches Matthew Macaluso, Michael Krams and Sheldon H. Preskorn
    5. Phase II development and the path to personalized medicine in CNS disease Douglas E. Feltner and Kenneth R. Evans
    6. CNS drug development – Phase III Judith Dunn, Penny Randall and Amir Kalali
    7. Statistics issues relevant to CNS drug development Craig H. Mallinckrodt, William R. Prucka and Geert Molenberghs
    8. Clinical trials management at company level Nuala Murphy
    9. Clinical trials management at the site level Joseph Kwentus
    10. Medical writing for CNS indications Ginette Nachman
    11. Dissemination of clinical trial information: multiple audiences, multiple formats Leslie Citrome
    12. The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date Philip D. Harvey and Richard S. E. Keefe
    13. Leveraging disruptive technologies to drive innovation in CNS clinical drug development Penny Randall, Judith Dunn and Amir Kalali
    Index.

  • Editors

    Amir Kalali, University of California, San Diego
    Amir Kalali is Vice President, Medical and Scientific Services, and Global Therapeutic Team Leader (CNS) at Quintiles Inc. He is also Professor of Psychiatry at the University of California San Diego, San Diego, CA, USA.

    Sheldon Preskorn, University of Kansas School of Medicine
    Sheldon Preskorn is Professor and Chairman, Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine, Wichita, KS, USA.

    Joseph Kwentus, University of Mississippi
    Joseph Kwentus is Clinical Professor at the University of Mississippi Medical Center, Jackson, MS, USA.

    Stephen M. Stahl, University of California, San Diego
    Stephen M. Stahl is Adjunct Professor of Psychiatry at the University of California San Diego, San Diego, and the Neuroscience Education Institute, Carlsbad, CA, USA.

    Contributors

    Sheldon H. Preskorn, Gwen L. Zornberg, Alan J. Cross, Frank D. Yocca, Matthew Macaluso, Michael Krams, Douglas E. Feltner, Kenneth R. Evans, Judith Dunn, Penny Randall, Amir Kalali, Craig H. Mallinckrodt, William R. Prucka, Geert Molenberghs, Nuala Murphy, Joseph Kwentus, Ginette Nachman, Leslie Citrome, Philip D. Harvey, Richard S. E. Keefe

related journals

Sign In

Please sign in to access your account

Cancel

Not already registered? Create an account now. ×

Sorry, this resource is locked

Please register or sign in to request access. If you are having problems accessing these resources please email lecturers@cambridge.org

Register Sign in
Please note that this file is password protected. You will be asked to input your password on the next screen.

» Proceed

You are now leaving the Cambridge University Press website. Your eBook purchase and download will be completed by our partner www.ebooks.com. Please see the permission section of the www.ebooks.com catalogue page for details of the print & copy limits on our eBooks.

Continue ×

Continue ×

Continue ×

Find content that relates to you

This site uses cookies to improve your experience. Read more Close

Are you sure you want to delete your account?

This cannot be undone.

Cancel

Thank you for your feedback which will help us improve our service.

If you requested a response, we will make sure to get back to you shortly.

×
Please fill in the required fields in your feedback submission.
×